News | October 13, 2025
Cadila launches allergy relief tablet Dlorfast-M
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
Subscribe To Our Newsletter & Stay Updated
